Impact of COVID-19 on patients with atopic dermatitis

[1]  Vineet D. Menachery,et al.  Type I Interferon Susceptibility Distinguishes SARS-CoV-2 from SARS-CoV , 2020, Journal of Virology.

[2]  Jashin J. Wu,et al.  Assessing the risk of dupilumab use for atopic dermatitis during the COVID-19 pandemic , 2020, Journal of the American Academy of Dermatology.

[3]  P. Calzavara-Pinton,et al.  Management of adult patients with severe atopic dermatitis treated with dupilumab during COVID‐19 pandemic: A single‐center real‐life experience , 2020, Dermatologic Therapy.

[4]  S. Lipner,et al.  Considerations for safety in the use of systemic medications for psoriasis and atopic dermatitis during the COVID‐19 pandemic , 2020, Dermatologic therapy.

[5]  G. Fabbrocini,et al.  Safety of dupilumab in atopic patients during COVID-19 outbreak , 2020, The Journal of dermatological treatment.

[6]  C. Bachert,et al.  COVID-19 in a patient with severe chronic rhinosinusitis with nasal polyps during therapy with dupilumab , 2020, Journal of Allergy and Clinical Immunology.

[7]  A. Tommasini,et al.  Recent Insight into SARS-CoV2 Immunopathology and Rationale for Potential Treatment and Preventive Strategies in COVID-19 , 2020, Vaccines.

[8]  A. Belloni Fortina,et al.  SARS‐CoV‐2 asymptomatic infection in a patient under treatment with dupilumab , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[9]  M. Merad,et al.  Immunology of COVID-19: Current State of the Science , 2020, Immunity.

[10]  E. Bleecker,et al.  COVID-19, asthma, and biological therapies: What we need to know , 2020, World Allergy Organization Journal.

[11]  A. Carugno,et al.  No evidence of increased risk for Coronavirus Disease 2019 (COVID‐19) in patients treated with Dupilumab for atopic dermatitis in a high‐epidemic area – Bergamo, Lombardy, Italy , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[12]  E. Berti,et al.  Safety of dupilumab in severe atopic dermatitis and infection of Covid‐19: two case reports , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[13]  C. Flohr,et al.  European Task Force on Atopic Dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARS‐Cov‐2) infection and atopic dermatitis , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[14]  J. Geraci,et al.  Repurposing Dupilumab May Treat Advanced COVID-19 Patients With Severe Acute Respiratory Syndrome By Mitigating Cytokine Storm , 2020 .

[15]  M. Ardeleanu,et al.  Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2). , 2019, Journal of dermatological science.

[16]  L. Purcell,et al.  Dupilumab does not affect correlates of vaccine‐induced immunity: A randomized, placebo‐controlled trial in adults with moderate‐to‐severe atopic dermatitis , 2019, Journal of the American Academy of Dermatology.

[17]  A. Muraro,et al.  Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

[18]  I. Pavord,et al.  Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma , 2018, Advances in Therapy.

[19]  M. Shirley.  Dupilumab: First Global Approval , 2017, Drugs.

[20]  E. R. Sutherland,et al.  Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial. , 2016, JAMA.

[21]  G. Yancopoulos,et al.  Targeting key proximal drivers of type 2 inflammation in disease , 2015, Nature Reviews Drug Discovery.

[22]  G. Yosipovitch,et al.  Mediators of Chronic Pruritus in Atopic Dermatitis: Getting the Itch Out? , 2016, Clinical Reviews in Allergy & Immunology.

[23]  M. Wills-Karp,et al.  IL-4 and IL-13 signaling in allergic airway disease. , 2015, Cytokine.

[24]  J. Spergel,et al.  From atopic dermatitis to asthma: the atopic march. , 2010, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.